In February 2018, the FDA and CDC approved the recommendation for a new hepatitis B vaccine, Heplisav-B targeting adults over the age of 18. The U.S. Food and Drug Administration (FDA) had twice rejected the application for licensure for Heplisav-B in the past four years because of safety signals. Heplisav-B differs from other licensed hepatitis B vaccines in that it contains a new synthetic adjuvant known as cytosine phosphoguanine 1018 (CpG 1018) composed of short synthetic DNA molecules. In 2016, the FDA rejected an application for licensure for the Heplisav-B vaccine, because the agency was concerned about an increased rate of heart attacks and deaths in people who had been given the vaccine. During the trial, approximately 14 subjects had heart attacks. In July 2017, the FDA committee convened to re-evaluate the scientific evidence and make a decision on whether Heplisav B should or should not be approved for use in the U.S. This committee had only one cardiologist on the team, Milton Packer, MD, who is a distinguished scholar in cardiovascular science at the Baylor University Medical Center in Dallas, Texas. According to Dr. Packer, it was possible that the Heplisav B vaccine’s novel adjuvant was related to the higher number of heart attacks in study participants who received the experimental vaccine. He stated: “To know if the 7 -1 heart attack imbalance represented a real risk, we’d need comparative data in 50,000 people.” However, the only way to conduct such a large trial would be to approve the vaccine and see what happens in the public. With Dr. Packer abstaining in his vote to recommend the vaccine, the FDA committee approved it anyway. Dr. Packer stated: “Why did I abstain? Based on the available data, it was impossible for anyone to know if the increase in heart attack risk was real. There is a simple rule in life: if you don’t know, you should say you don’t know.” The vaccine is now available to the public, and all those who receive it are basically guinea pigs to find out if heart attacks will result from the experimental vaccine, and if it will continue to have FDA approval.
Non-invasive therapy to reduce the body
burden of aluminium in Alzheimer’s disease
Abstract. There are unexplained links between human exposure to aluminium and the incidence, progression and aetiology of Alzheimer’s disease. The null hypothesis which underlies any link is that there would be no Alzheimer’s disease in the effective absence of a body burden of aluminium. To test this the latter would have to be reduced to and retained at a level that was commensurate with an Alzheimer’s disease-free population. In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium. This same mechanism might now be applied to both the removal of aluminium from the body and the reduced entry of aluminium into the body while ensuring that essential metals, such as iron, are unaffected. Based upon the premisethat urinary aluminium is the best non-invasive estimate of body burden of aluminium patients with Alzheimer’s disease were asked to drink 1.5 L of a silicic acid-rich mineral water each day for five days and, by comparison of their urinary excretion of aluminium pre-and post this simple procedure, the influence upon their body burden of aluminium was determined. Drinking the mineral water increased significantly (P <0.001) their urinary excretion of silicic acid (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol
creatinine) and concomitantly reduced significantly (P = 0.037) their urinary excretion of aluminium (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). The latter was achieved without any significant (P >0.05) influence upon the urinary excretion of iron (20.7 ± 9.5 to 21.7 ± 13.8 nmol/mmol creatinine). The reduction in urinary aluminium supported the future longer-term
use of silicic acid as non-invasive therapy for reducing the body burden of aluminium in Alzheimer’s disease.
First Experimental Study on Baby Mice Finds Autism-like Response to Common Vaccine Ingredient
A breakthrough study by scientists from the University of British Columbia in Vancouver, Canada has been published in the Journal of Inorganic Biochemistry demonstrating that significant correlations exist between rates of Autism Spectrum Disorder (ASD) and total aluminum adjuvants given to children through vaccines in several Western countries.
This is the first experimental study to demonstrate that aluminum adjuvants can impair social behavior if applied in the early period of postnatal development.
An infant in the United States, in its first two years, usually receives 27 vaccines as part of the routine pediatric vaccination schedule; many of which contain aluminum adjuvants.
On Day 1 of life, infants receive 17 times more aluminum than would be allowed if doses were adjusted per body weight.
FDA regulations require safety testing of constituent ingredients in drugs (21 CFR 610.15). With the exception of extraneous proteins, no component safety testing is required for vaccines or vaccine schedules. The dosing of aluminum in vaccines is based on the production of antibody titers, not safety science. Here we estimate a Pediatric Dose Limit that considers body weight. We identify several serious historical missteps in past analyses of provisional safe levels of aluminum in vaccines, and provide updates relevant to infant aluminum exposure in the pediatric schedule considering pediatric body weight
The small quantity of aluminum retained in the body
accumulates over time. Most of the aluminum that accumulates
(50 to 60 percent) settles in the bones, some in the lungs (about 25
percent) and some in the brain (about 1 percent). The remaining
quantities are distributed in serum, skin, gastrointestinal tract, lymph
nodes and glands. In fact, low quantities of aluminum can be found
in most organs.
VLA comment: Apparently it is okay with the CDC and Paul Offit at the Philadelphia Children’s Hospital that…and I quote and excerpt…the process which a small infant has to deal with excreting this poison or the consequences of retain the metal in the bones or the brains is inconsequental:
Pharmacokinetics and Differential Regulation of Cytochrome P450 Enzymes in Type 1 Allergic Mice
“We investigated hepatic P450 metabolism and drug pharmacokinetics in type 1 allergic mice induced by ovalbumin (OVA) emulsified with aluminum and inactive Bordetella pertussis. To further propose a possible key factor in drug-allergic disease interactions, we examined the inhibitory effect of NO, a marker of allergic conditions on the activities of major P450 isoforms”.
VLA COMMENT-CD RE: FLUORIDE: There may be a miniscule amount of natural fluoride that exists in the soils and is released just like other minerals. I wonder FLUORIDE being less toxic in its natural state than the much more reactive state that is in the fluoride compounds added to water. I have only seen positive effects from people drinking Fiji water – the benefits of getting rid of the aluminum are so great, and I see it as a time/toxicity equation. That a 3-6 month intensive course of Fiji water to lower the body burden of aluminum is of such benefit, that it does not need to be consumed forever to reap benefits, and there are other likely ways to protect against any miniscule fluoride exposure (like taking vitamin c and other antioxidants) that it is worth consuming it if aluminum toxicity is suspected. Our studies show that ALL people with a level of greater than 1mcg/g of dry brain weight have pathology that is associated with Alzheimer’s, or autism (depending on the age) and no brains examined with these levels were healthy. All healthy brains had less than 1 mcg of aluminum per gram of dry brain weight. It is not debatable anymore.
In addition, people with the aggressive form of MS excreted far more aluminum in their urine than healthy people, and when their aluminum body burden was reduced by drinking silica rich mineral water, they did not have any progression of their disease. The study was not designed to measure improvement in their condition, but we would have likely seen improvement if the study was designed with that outcome. A facebook group has formed called Fiji Water Detox and Epilepsy support Group and parents are reporting that their children are stopping or drastically reducing the number of seizures per day when consuming Fiji water (sometimes the kids had hundreds of seizures a day which stopped overnight when they started drinking Fiji). The benefits far outweigh any risks, and getting the aluminum out should be the highest priority for anyone dealing with a chronic, complex, inflammatory health problem.
In a nutshell, scientists all over the world have learned the following about aluminum adjuvant, most of it since 2010 (not a single one of these new discoveries or published studies was considered in Dr. Mitkus’ paper).
From Canada, 2012: “Aluminum (Al) is highly neurotoxic and has been shown to impair both prenatal and postnatal brain development in humans and experimental animals.” From France, 2013: “However, continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe, especially in the case of overimmunization or immature/altered blood brain barrier…” From France, 2015: “Thus alum and other poorly biodegradable materials taken up at the periphery by phagocytes circulate in the lymphatic and blood circulation and can enter the brain using a Trojan horse mechanism similar to that used by infectious particles. Previous experiments have shown that alum administration can cause CNS dysfunction and damage, casting doubts on the exact level of alum safety.” From France, 2016: “We conclude that Alhydrogel [aluminum adjuvant] injected at low dose in mouse muscle may selectively induce long-term Al cerebral accumulation and neurotoxic effects.” From England, 2017: “The amount of aluminum in the brain tissue was, I would say, extraordinarily high. Very high. My group has measured the aluminum content of probably more than one hundred human brains, and these brain tissues taken from the individuals with a diagnosis of autism were some of the highest we’ve measured bar none. The only ones we’ve seen that are similar were a recent study of familial Alzheimer’s. This in itself is a very important finding.”
So, versus ten years ago, scientists now know that aluminum adjuvant, when injected, can 1) impair brain development, 2) remain in the brain much longer than thought, 3) is brought into the brain by macrophages that grab the aluminum from the vaccine injection site and recirculate it, 4) may actually be worse when injected in small doses repeatedly (like it’s done during vaccination), and 4) there’s remarkably high levels of aluminum in the brains of people diagnosed with autism.Dr. Chris Exley, the author of this most recent study (#5, and the subject of my recent article) was so moved by the results of his study he said the following:
The total number of mcgs of Aluminum by 18 years old is 13,538 mcgs.
VLA Comment:These researchers and other moral saviors behind the scenes of public awareness (CD, CB, PK, GG, MDG, Cong B, Cong P…on and on) are the same dedicated persons who blew the whistle on Mercury in vaccines and dental fillings. Most mercury was taken out of vaccines in 2001. At one time mercury was in 16 vaccine doses, debilitating our children, causing them to be diagnosed as “mentally ill”, OCD, Bipolar, ADHD, Autism; prescribed psychiatric drugs as young a 0-1 years old.However, Mercury is still in vaccines today (see chart above).
Mercury and aluminum are both ” heavy metals”. Heavy Metals are causing malfunction; electrical malfunction, immune dysfunction, digestive disorder in every incoming generation of humanity. Metals do not belong in the human physiology. Adults are now spending thousands of dollars trying to get heavy metals out of their systems. Where do you think these deposits came from? If heavy metals negatively affect the outer environment it would be common sense to conclude that they would be harmful to the inner environment of man…and especially dangerous our young children and pregnant moms.
Link CDC Cover up: 4,250% increase in miscarriage reports from flu shots
According to IMS Health’s Vector One: National and Total Patient Tracker Database for 2013 these are the figures for 0-1-year-olds being prescribed psychiatric drugs:
249,669 0-1 year olds are on anti-anxiety drugs (such as Xanax, Klonopin, and Ativan).
26,406 0-1 year olds are on antidepressants (such as Prozac, Zoloft, and Paxil).
There are 1,422 0-1 year olds taking ADHD drugs (such as Ritalin, Adderall, and Concerta).
654 0-1 year olds are taking antipsychotics (such as Risperdal, Seroquel, and Zyprexa).
While the CDC was correct in issuing their report on the 10,000 2-3 year olds (toddlers) being prescribed ADHD drugs, the number of toddlers on anti-anxiety and antidepressants is staggering in comparison:
318,997 2-3 year olds are on anti-anxiety drugs.
46,102 2-3 year olds are on antidepressants.
3,760 2-3 year olds are taking antipsychotics.
And as for other age groups, the numbers start in the millions with 0-5 year olds:
The total number of 0-5 year olds currently prescribed psychiatric drugs is 1,080,168.
The number of 6-12 year olds on psychiatric drugs is 4,130,340.
The number of 13-17 year olds taking psychiatric drugs is 3,617,593.
Sep 1, 2017 – The group of most concern are known as the heavy metals and includes mercury, lead, cadmium, aluminium, and arsenic. The definition of what constitutes a heavy metal is vague and various criteria have been proposed based on density, atomic weight or atomic number, or various chemical properties and toxicity 1.